|
gptkbp:instanceOf
|
gptkb:biotechnology
gptkb:drug
|
|
gptkbp:age
|
patients aged 4 to 17 years
|
|
gptkbp:approvalYear
|
2020-01-31
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
V01AA11
|
|
gptkbp:clinicalTrialPhase
|
gptkb:ARTEMIS
gptkb:PALISADE
|
|
gptkbp:contraindication
|
history of eosinophilic esophagitis
uncontrolled asthma
|
|
gptkbp:firstBook
|
yes
|
|
gptkbp:form
|
capsule
powder
sachet
|
|
gptkbp:genericName
|
gptkb:peanut_allergen_powder-dnfp
|
|
gptkbp:hasBoxedWarning
|
anaphylaxis
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Palforzia
|
|
gptkbp:indication
|
treatment of peanut allergy
|
|
gptkbp:initialDoseEscalation
|
0.5 mg to 6 mg peanut protein
|
|
gptkbp:mainIngredient
|
peanut protein
|
|
gptkbp:maintenanceDose
|
300 mg peanut protein
|
|
gptkbp:manufacturer
|
gptkb:Aimmune_Therapeutics
|
|
gptkbp:marketedIn
|
gptkb:United_States
|
|
gptkbp:pregnancyCategory
|
not assigned
|
|
gptkbp:prescriptionRequired
|
https://www.palforzia.com/hcp/prescribing-information
|
|
gptkbp:prescriptionStatus
|
prescription only
|
|
gptkbp:requiresREMS
|
yes
|
|
gptkbp:riskFactor
|
anaphylaxis
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
vomiting
diarrhea
abdominal pain
cough
itching
anaphylaxis
rash
urticaria
dyspnea
wheezing
throat irritation
oral pruritus
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:treatment
|
oral immunotherapy
|
|
gptkbp:upDosing
|
3 mg to 300 mg peanut protein
|
|
gptkbp:website
|
https://www.palforzia.com/
|
|
gptkbp:bfsParent
|
gptkb:Aimmune_Therapeutics
|
|
gptkbp:bfsLayer
|
7
|